{"id":11477,"date":"2010-11-04T00:00:00","date_gmt":"2010-11-03T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2010\/11\/04\/nuevos-datos-validan-la-eficacia-de-un-tratamiento-contra-las-leucemias-patentado-por-investigadores-espanoles\/"},"modified":"2020-05-12T15:26:13","modified_gmt":"2020-05-12T13:26:13","slug":"nuevos-datos-validan-la-eficacia-de-un-tratamiento-contra-las-leucemias-patentado-por-investigadores-espanoles","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2010\/11\/nuevos-datos-validan-la-eficacia-de-un-tratamiento-contra-las-leucemias-patentado-por-investigadores-espanoles\/","title":{"rendered":"Nuevos datos validan la eficacia de un tratamiento contra las leucemias patentado por investigadores espa\u00f1oles"},"content":{"rendered":"<p>AICAR es la primera mol\u00e9cula terap\u00e9utica contra el c\u00e1ncer patentada por un centro p\u00fablico espa\u00f1ol que ha llegado a la fase de ensayo cl\u00ednico. El f\u00e1rmaco fue desarrollado el a\u00f1o 2003 por investigadores del actual grupo de Apoptosis y c\u00e1ncer del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) y del Departamento de Ciencias Fisiol\u00f3gicas II de la Universidad de Barcelona (UB), liderado por Joan Gil. El a\u00f1o 2004, los derechos de desarrollo y explotaci\u00f3n del producto fueron adquiridos por la empresa Advancell, que lo produce con el nombre comercial de Acadra\u2122. <b><br \/> El f\u00e1rmaco act\u00faa activando mecanismos de muerte programada (apoptosis) en las c\u00e9lulas tumorales de la leucemia linfoc\u00edtica cr\u00f3nica y en otros c\u00e1nceres de c\u00e9lulas B como el linfoma de c\u00e9lulas de manto y el linfoma espl\u00e9nico de la zona marginal. <b><br \/> La ventaja del medicamento es que es capaz de actuar en las c\u00e9lulas malignas sin atacar a las sanas. Los f\u00e1rmacos existentes actualmente eliminan las c\u00e9lulas T sanas (que forman parte del sistema inmunol\u00f3gico que defiende el organismo de las infecciones), junto con las tumorales, hecho que inmunodeprime a los pacientes. <b><br \/> Hasta ahora, la \u00fanica diana molecular conocida de AICAR era la prote\u00edna quinasa activada por AMP (AMPK). Ahora, el estudio publicado en Blood, coordinado por Joan Gil y del cual son primeros coautores los investigadores del IDIBELL y la UB Antonio F. Santidri\u00e1n y Diana M Gonz\u00e1lez-Giron\u00e8s, ha demostrado que AICAR induce apoptosis en los linfocitos B mediante un mecanismo independiente de AMPK. El estudio demuestra c\u00f3mo AICAR induce apoptosis en c\u00e9lulas con mutaciones en el gen supresor tumoral p53. <b><br \/> Seg\u00fan el coordinador de la investigaci\u00f3n, Joan Gil, \u201cesto significa que AICAR podr\u00eda ser una alternativa terap\u00e9utica interesante para los pacientes de leucemia linfoc\u00edtica cr\u00f3nica con la funci\u00f3n de p53 alterada y resistentes a la quimioterapia convencional\u201d. <b><br \/> AICAR ha superado estudios precl\u00ednicos, que evaluaron la toxicidad y la farmacodin\u00e1mica del f\u00e1rmaco. El a\u00f1o 2007 se aprob\u00f3 un ensayo cl\u00ednico en enfermos de leucemia linfoc\u00edtica cr\u00f3nica, que est\u00e1 actualmente en marcha, y sobre el cual se presentar\u00e1n los primeros resultados pr\u00f3ximamente. <b><br \/> La investigaci\u00f3n ha contado con la colaboraci\u00f3n del Servicio de Hematolog\u00eda Cl\u00ednica del Instituto Catal\u00e1n de Oncolog\u00eda y del Servicio de Hematolog\u00eda del Hospital Universitario de Bellvitge. Tambi\u00e9n han participado investigadores del Hospital Universitario Marqu\u00e9s de Valdecilla de Santander, del Innsbruck Medical University de Austria, del Instituto Cochin de la Universidad Par\u00eds Descartes de Francia. <b><br \/> <strong>Referencia del art\u00edculo<\/strong> <strong><b><br \/><\/strong> <strong>Santidri\u00e1n AF*<\/strong>, <strong>Gonz\u00e1lez-Giron\u00e8s DM*<\/strong>, <strong>Iglesias-Serret D*<\/strong>, <strong>Coll-Mulet L*<\/strong>, <strong> Cosialls AM*<\/strong>, <strong>de Frias M*<\/strong>, <strong>Camp\u00e0s C*<\/strong>, <strong>Gonz\u00e1lez-Barca E*<\/strong>, <strong>Alonso E*<\/strong>, Labi V, Viollet B, Benito A, <strong>Pons G<\/strong>*, Villunger A, <strong>Gil J*<\/strong>.  AICAR induces apoptosis independently of AMPK  and p53 through  up-regulation of the BH3-only proteins BIM and NOXA in  chronic  lymphocytic leukemia cells. Blood, 2010 Oct 21;116(16).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Publicado en la revista Blood Referencia del art\u00edculo  Santidri\u00e1n AF* Gonz\u00e1lez-Giron\u00e8s DM* Iglesias-Serret D* Coll-Mulet L* Cosialls AM* de Frias M* Camp\u00e0s C* Gonz\u00e1lez-Barca E* Alonso E* Pons G Gil J*<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[246,281],"tags":[],"class_list":["post-11477","post","type-post","status-publish","format-standard","hentry","category-apoptosis-y-cancer","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2024-11-28 23:14:22","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11477"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11477\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}